MD, PhD, Research Fellow in Headache disorders, @georgeinstitute, conjoint senior lecturer @unsw, Australia. Social Media Editor @JCephalalgia, #BigHeadPain
🤖 AI didn't create sloppy science. It made it easier!
A new paper warns about fabricated citations, citation laundering and trusting polished AI-generated text.
The twist? The author used AI to write it—while checking its claims.
💬 Thoughts?
📖 doi.org/10.1007/s10459-026-1…
🧠 Migraine is chronic — but its frequency varies.
Carl Cincinnato and I have published a letter in Cephalalgia asking whether “episodic migraine” and “chronic migraine” are still the best terms.
💬 What do you think?
📖 doi.org/10.1177/033310242615…
~4 million Australians live with migraine.
Yet our new paper found just ONE NHMRC/MRFF-funded headache clinical trial from 2013–2025, and NONE for migraine or tension-type headache.
We need stronger investment and research capacity.
New in Cephalalgia Reports!
Headache disorders are a leading cause of disability, yet publicly funded headache clinical trials in Australia are remarkably scarce. This new paper highlights the gap and the opportunity for change.
Article highlights
•
No funded clinical trials were identified for migraine or tension-type headache, despite their substantial burden.
•
A review of NHMRC and MRFF funding in Australia identified only one funded headache disorder clinical trial since 2013, focused on cluster headache.
•
Increased investment in headache clinical trials, workforce development, and national research infrastructure could help accelerate evidence generation and improve patient outcomes.
journals.sagepub.com/doi/10.…#migraine#headache#brain#pain#neurology#neuroscience@faradoost
New in Cephalalgia Reports!
Headache disorders are a leading cause of disability, yet publicly funded headache clinical trials in Australia are remarkably scarce. This new paper highlights the gap and the opportunity for change.
Article highlights
•
No funded clinical trials were identified for migraine or tension-type headache, despite their substantial burden.
•
A review of NHMRC and MRFF funding in Australia identified only one funded headache disorder clinical trial since 2013, focused on cluster headache.
•
Increased investment in headache clinical trials, workforce development, and national research infrastructure could help accelerate evidence generation and improve patient outcomes.
journals.sagepub.com/doi/10.…#migraine#headache#brain#pain#neurology#neuroscience@faradoost
🇩🇪 I'll be at #EHF2026 in Berlin, 9–12 December! Our research on calcium channel blockers and headache (113 randomised trials) has been accepted as an ePoster. Looking forward to meeting colleagues and friends. Are you attending? Please let me know! #HeadacheResearch
Excited to share a new Call for Papers in Cephalalgia — the official journal of the International Headache Society.
🧠 Special Issue: Managing and Understanding Headache in the Context of Comorbid Conditions
Guest Editors: Faraidoon Haghdoost and Henrik Winther Schytz
Headache disorders such as migraine and tension-type headache rarely exist in isolation. They often sit alongside high blood pressure, dyslipidaemia, depression, anxiety, gastrointestinal disorders, and more. This special issue focuses on integrated, real-world approaches to care — from shared pathophysiology and overlapping risk factors to multidisciplinary management and treatments that address both headache and comorbid conditions.
We welcome:
• Original research and clinical trials
• Systematic reviews and network meta-analyses
• Real-world evidence
• Viewpoints and perspectives
If your work explores headache in the context of comorbidities — cardiovascular, mental health, gastrointestinal, or beyond — we would love to hear from you.
📅 Submission deadline: 31 December 2026
📌 Please note in your cover letter that your manuscript is for the “Headache and Comorbidities” special issue.
Let’s move toward more holistic, patient-centred headache care. Looking forward to your submissions and to advancing this important conversation together.
surl.lt/wadtdt#migraine#headache#brain#pain#neurology#neuroscience@faradoost@Simona_Sacco_@HenrikSchytz
Excited to share a new Call for Papers in Cephalalgia — the official journal of the International Headache Society.
🧠 Special Issue: Managing and Understanding Headache in the Context of Comorbid Conditions
Guest Editors: Faraidoon Haghdoost and Henrik Winther Schytz
Headache disorders such as migraine and tension-type headache rarely exist in isolation. They often sit alongside high blood pressure, dyslipidaemia, depression, anxiety, gastrointestinal disorders, and more. This special issue focuses on integrated, real-world approaches to care — from shared pathophysiology and overlapping risk factors to multidisciplinary management and treatments that address both headache and comorbid conditions.
We welcome:
• Original research and clinical trials
• Systematic reviews and network meta-analyses
• Real-world evidence
• Viewpoints and perspectives
If your work explores headache in the context of comorbidities — cardiovascular, mental health, gastrointestinal, or beyond — we would love to hear from you.
📅 Submission deadline: 31 December 2026
📌 Please note in your cover letter that your manuscript is for the “Headache and Comorbidities” special issue.
Let’s move toward more holistic, patient-centred headache care. Looking forward to your submissions and to advancing this important conversation together.
surl.lt/wadtdt#migraine#headache#brain#pain#neurology#neuroscience@faradoost@Simona_Sacco_@HenrikSchytz
Completely agree -- migraines are a very low priority when it comes to funding -- and it's a real shame! This condition is also quite misunderstood by the general public. As a migraineur myself, I've written about this.
mariamalyk.com/sociologicall…
A breakthrough in stroke care 🧠 Jersey Shore University Medical Center is using cutting-edge MRI technology to help identify patients who may benefit from life-saving treatment even when they wake up with stroke symptoms & don’t know when it started.
patch.com/new-jersey/asbury-…
~4 million Australians live with migraine.
Yet our new paper found just ONE NHMRC/MRFF-funded headache clinical trial from 2013–2025, and NONE for migraine or tension-type headache.
We need stronger investment and research capacity.
doi.org/10.1177/251581632615…#headache#migraine
RESEARCH ARTICLE: Association Between Follow-Up Mean Blood Pressure and Blood Pressure Control: A Meta-Regression Analysis of 101 Randomized Trials @faradoostahajrnls.org/4k5K2nD
Better migraine treatments mean little if patients cannot access them.
Pleased to have reviewed and endorsed this paper calling for fairer PBS access and more affordable migraine care.
Please read, share and help raise awareness!
headacheaustralia.org.au/wp-…
🧠 Migraine is more than just a headache!
🌍 1.16 billion people affected worldwide.
⚡ One of the leading causes of disability, with impacts extending far beyond headache attacks.
Swipe through 4 key facts from the latest Lancet review (2026).
#migrainethelancet.com/journals/lance…
Do anti-CGRP migraine medications increase blood pressure?
We analysed FDA data from 20 RCTs and 18,886 participants.
Reassuringly, neither anti-CGRP monoclonal antibodies nor gepants were associated with significant increases in BP vs placebo.